A Menopause Sleep Supplement Added 41 Minutes of Sleep in Three Weeks

Sleep disruption during menopause is often blamed on hot flashes and night sweats. A new randomized trial focused on a different group: women whose sleep was poor even though vasomotor symptoms were minimal. After only three weeks, women taking a non-sedating multi-ingredient supplement slept about 41 minutes longer per night, while sleep time in the placebo group fell by about 15 minutes. The supplement also produced a 90.9% sleep-disturbance responder rate compared with 45.2% on placebo.

For a short supplement trial, those are unusually large and immediately understandable differences.

The study targeted sleep problems beyond hot flashes

Researchers enrolled 128 healthy perimenopausal and postmenopausal women with moderate-to-severe sleep disturbance. Unlike many menopause sleep studies, participants were specifically selected to have a low burden of vasomotor symptoms, defined as no more than five hot flashes and two night sweats per week.

That distinction matters. Menopause-related sleep problems are often treated as a consequence of waking up hot or sweaty, but sleep can deteriorate even when those symptoms are relatively minor.

Participants were randomly assigned in double-blind fashion to placebo or a neurotransmitter-modulating supplement containing L-theanine, gamma-aminobutyric acid, magnesium, S-adenosyl methionine and propyl gallate.

The intervention lasted three weeks. Of the 128 women randomized, 127 completed the trial, leaving unusually little attrition for a short decentralized study.

The primary outcomes were standardized PROMIS measures of sleep disturbance and sleep-related daytime impairment. Researchers also collected sleep diaries covering total sleep time and sleep efficiency.

The sleep-duration difference was hard to ignore

The most striking result was total sleep time.

Women taking the supplement reported sleeping 40.9 minutes longer by the end of the trial. The placebo group, meanwhile, reported sleeping 14.9 minutes less.

That produces an approximate 55.8-minute separation in change between the two groups.

For someone regularly losing sleep, an hour-sized nightly difference is potentially meaningful in a way that a statistically significant but tiny questionnaire shift would not be.

Sleep efficiency also improved. The supplement group increased by 7.4%, compared with 3.4% in the placebo group.

The effects were not limited to diary-estimated sleep duration. The primary PROMIS Sleep Disturbance score improved significantly more with the supplement, with a least-squares mean difference of 11.1 points between groups by week 3.

All primary endpoints had already reached statistical significance by the second week.

Nine in ten women met the sleep-disturbance responder threshold

The responder analysis was another unusually strong result.

By week 3, 90.9% of women receiving the supplement qualified as responders on the PROMIS Sleep Disturbance measure, compared with 45.2% receiving placebo.

Sleep-related daytime impairment improved as well. The responder rate for that measure was 50.8% with the supplement and 32.2% with placebo.

That does not mean nine in ten women were cured of insomnia or suddenly became perfect sleepers. A responder threshold reflects a predefined degree of improvement on a standardized measure, not complete resolution of symptoms.

Still, the size of the separation is notable, particularly because placebo responses in sleep trials can be substantial.

What might the ingredients be doing?

The formulation was designed around several neurotransmitter systems involved in arousal and sleep regulation.

GABA is the brain's major inhibitory neurotransmitter. L-theanine has been investigated for effects on relaxation and stress-related arousal. Magnesium participates in numerous neural and metabolic processes, while S-adenosyl methionine is involved in methylation reactions and neurotransmitter metabolism.

But the study cannot tell us which ingredient mattered most, whether several ingredients acted together, or whether some ingredients contributed little at all.

That is one of the major limitations of combination products. A positive trial can establish that the tested formulation performed better than placebo without establishing that every ingredient in the bottle is necessary or independently effective.

The trial also described the formulation as non-sedating. That is potentially important for women who want better sleep without taking something designed simply to induce drowsiness. But longer studies would be needed to determine whether daytime alertness, tolerance or other effects remain favorable with continued use.

Three weeks is impressive, but still only three weeks

The speed of the response makes the findings attractive, but it also defines their biggest limitation.

Three weeks is enough to show a short-term effect. It is not enough to establish that the benefit remains after three months, a year or several years of menopausal sleep disruption.

The study was also relatively small. One hundred twenty-seven women completed it, which is adequate for detecting substantial short-term differences but far below the scale needed to characterize uncommon adverse effects or identify which types of women benefit most.

The sleep-duration outcome was diary based rather than measured entirely with laboratory polysomnography. That does not make it meaningless, because perceived sleep duration is itself clinically relevant, but objective replication would strengthen confidence in the magnitude of the effect.

The formulation also deserves careful scrutiny as a product. Independent replication, funding disclosures, author conflicts of interest and the exact doses of each ingredient matter before a branded multi-ingredient supplement should be treated as established therapy.

The result is still unusually strong for a supplement trial

Supplement research frequently produces small, inconsistent or poorly controlled effects. This study is interesting because it does not fit that pattern neatly.

It was randomized, double-blind and placebo controlled. Nearly every participant completed it. Multiple prespecified sleep outcomes improved. The primary endpoints separated from placebo quickly. And the most intuitive real-world outcome, nightly sleep duration, changed by an amount large enough for people to notice.

The result therefore deserves attention without being treated as the final word.

If independent studies reproduce a roughly 40-minute increase in sleep, show that it persists over months and confirm an acceptable safety profile, a non-sedating approach to menopausal sleep disruption could become genuinely useful.

For now, the strongest conclusion is simpler: in this trial, a multi-ingredient supplement produced a surprisingly large short-term improvement in sleep among menopausal women whose sleep problems were not primarily driven by hot flashes.

Scientific References & Further Reading

• Anchor Study: “Nonsedating neurotransmitter-modulating supplement for nonvasomotor sleep disturbance in menopause.” (Carbonneau S, Mysliwiec V, Doyle AL, et al. Menopause. 2026. doi:10.1097/GME.0000000000002880. PMID:42742055.)

---

Disclaimer: This article is for informational purposes only and does not constitute medical advice. It is not a substitute for diagnosis, treatment, or individualized medical care.